Director of the Thoracic Oncology Program at the Abramson Cancer Center, Corey Langer, MD, discusses recent interpretations of the mutational profile for non-small cell lung cancer (NSCLC), what this knowledge reveals about the patient population, and how it is being translated into clinical trials for new therapies targeting specific mutations in NSCLC.
Published
October 14, 2013
Created by
BROADCASTMED